The ARTO Transcatheter Mitral Valve Repair System

Moderate-to-severe mitral regurgitation is present in up to 74% of inpatients and 45% of outpatients with systolic heart failure, and the presence of functional mitral regurgitation (FMR) is associated with a higher mortality rate than for patients without FMR. The ARTO System is a unique endovascular therapy for mitral valve regurgitation associated with congestive heart failure. The ARTO System is currently being investigated in the MAVERIC (MitrAl ValvE RepaIr Clinical) trial program. MAVERIC is a prospective, multicenter, single arm group of studies evaluating the safety and performance of the ARTO System in patients with congestive heart failure associated with mitral regurgitation. Unique features of the ARTO System include a one-size device which can be customized to specific anatomies. The magnitude of benefit that patients will derive from transcatheter correction of FMR when compared to best medical therapy also remains to be determined by future and ongoing clinical trials.